In clinical trials of HIV-1 uninfected individuals, decreases in BMD were observed. In the iPrEx trial, a substudy of 503 subjects found mean changes from baseline in BMD ranging from –% to –% across total hip, spine, femoral neck, and trochanter in the TRUVADA group compared with the placebo group, which returned toward baseline after discontinuation of treatment. Thirteen percent of subjects receiving TRUVADA versus 6% of subjects receiving placebo lost at least 5% of BMD at the spine during treatment. Bone fractures were reported in % of the TRUVADA group compared with % in the placebo group. No correlation between BMD and fractures was noted [see Clinical Studies ]. The Partners PrEP trial found similar fracture rates between treatment and placebo groups (% and %, respectively); no BMD evaluations were performed during this trial [see Clinical Studies ].